Clinical Trial Update: Effects of Tetrahydrobiopterin (BH4) on Leg Blood Flow and Exercise Capacity in Patients With Peripheral Artery Disease [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating tetrahydrobiopterin (BH4) for leg blood flow and exercise capacity in Peripheral Artery Disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Artery Disease

Drugs mentioned

• tetrahydrobiopterin (tetrahydrobiopterin)

Snippet

Sponsor: University of Nebraska | Conditions: Peripheral Artery Disease, Peripheral Arterial Disease | Phase 4 | Status: WITHDRAWN